Dr. Vamsidhar Velcheti with the Cleveland Clinic joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses MET as a target in advanced non-small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss the changing landscape of first-line treatment of ALK-positive advanced non-small cell lung cancer.
Dr. Shirish Gadgeel is Co-Leader of the Thoracic Oncology Team in the Comprehensive Cancer Center at Michigan Medicine at the University of Michigan as of May 2017. He also has been appointed Associate Director for Cancer Care (ADCC) at Networking and Affiliated Centers.
Prior to joining Michigan Medicine Dr. Gadgeel was the co-leader of the Molecular Therapeutics Program of the Karmanos Cancer Institute (KCI).
Dr. Nathan Pennell received his Ph.D. in neuroscience in 1998 and his M.D. in 2002 from the University of Florida College of Medicine in Gainesville, FL. He then moved to Boston to do his internal medicine internship and residency training at Brigham & Women’s Hospital, and completed his medical oncology fellowship at the Dana Farber Cancer Institute, also in Boston. While there, he developed an expertise in lung cancer, mesothelioma, and thyroid cancer. He moved to the friendly midwest in 2008 to continue with this focus at the Taussig Cancer Institute at the Cleveland Clinic.
Dr. Alice Shaw joined GRACE to discuss patterns of resistance in ALK positive non small cell lung cancer.
Dr. Alice Shaw joined GRACE to discuss controlling brain metastases in patients with molecular driven advanced non-small cell lung cancer.
Alice T. Shaw is the Director of the Center for Thoracic Cancers and the Paula O’Keeffe Endowed Chair of Thoracic Oncology at Massachusetts General Hospital. She is also an Associate Professor of Medicine at Harvard Medical School. She received her A.B. in Biochemistry from Harvard and her M.D. and Ph.D. degrees from Harvard Medical School. She did her residency in Internal Medicine at Massachusetts General Hospital and completed a fellowship in Hematology/Oncology at Dana-Farber/Massachusetts General Hospital. She completed her postdoctoral work in the laboratory of Dr.
Karen Reckamp, MD, MS, is Associate Professor in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center (COHCCC). She received her medical degree from University of Chicago, and her master’s degree in Clinical Investigation from UCLA. She completed residency training in Internal Medicine at Barnes-Jewish Hospital and a Hematology/Oncology fellowship at the David Geffen School of Medicine at UCLA.
Matt Hiznay is a five-year survivor of metastatic, ALK-positive non-small cell lung cancer. He was born in Youngstown, Ohio, and grew up in the small town of Poland, Ohio. Matt graduated from Poland Seminary High School in 2006 and from John Carroll University in 2010 with a Bachelor of Science degree magna cum laude.